Live tape
Top 8, mentions 7d7,506META2,263 mentions▲ +0.06GOOGL1,504 mentions▲ +0.02NVDA797 mentions▲ +0.09MUSE665 mentions▲ +0.07MSFT602 mentions▲ +0.05SPY568 mentions▲ +0.05QQQ557 mentions▲ +0.08TSLA550 mentions▲ +0.06

Equity · Healthcare

AVTX

Avalo Therapeutics, Inc. · NasdaqCM

$15.47 −1.46% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 25, 2026
Price · Chart
Our own end-of-day closes 62 sessions
$22 $14 30 Jun 25 Sep

The line runs $18 on 30 June through $15.47 on 25 September, on a scale from $14 to $22. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of AVTX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 62 sessions over that window: $18 on 30 June 2026 through $15.47 on 25 September 2026.

Market cap $829.7M
52-week range $10.79 – $24
Avg volume 62.1K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 25, 2026

AVTX insider trades

SEC Form 4 · last 90 days · newest reported trade 16 Sep 2026
Open-market buys 0
Open-market sells 10
Net sold $2.04M
Non-trade filings 9
Date Insider Type Shares Value
16 Sep 2026 Sullivan Christopher Ryan Chief Financial Officer Sell 12,394 $202K
10 Sep 2026 Sullivan Christopher Ryan Chief Financial Officer Sell 10,185 $179K
28 Aug 2026 Doyle Mittie Chief Medical Officer Sell 679 $14K
18 Aug 2026 Sullivan Christopher Ryan Chief Financial Officer Sell 31,031 $622K
17 Aug 2026 Sullivan Christopher Ryan Chief Financial Officer Sell 41,694 $828K
17 Aug 2026 Doyle Mittie Chief Medical Officer Sell 1,000 $20K
11 Aug 2026 Riley Jennifer Chief Strategy Officer Sell 2,655 $52K
10 Aug 2026 Doyle Mittie Chief Medical Officer Sell 679 $14K
27 Jul 2026 Doyle Mittie Chief Medical Officer Sell 1,000 $20K
30 Jun 2026 Doyle Mittie Chief Medical Officer Sell 4,654 $93K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
16 Sep 2026 Sullivan Christopher Ryan Chief Financial Officer Option exercise 12,394 $122K
10 Sep 2026 Sullivan Christopher Ryan Chief Financial Officer Option exercise 10,185 $82K
28 Aug 2026 Doyle Mittie Chief Medical Officer Option exercise 679 $5K
18 Aug 2026 Sullivan Christopher Ryan Chief Financial Officer Option exercise 31,031 $307K
17 Aug 2026 Sullivan Christopher Ryan Chief Financial Officer Option exercise 40,821 $403K
17 Aug 2026 Doyle Mittie Chief Medical Officer Option exercise 1,000 $13K
10 Aug 2026 Doyle Mittie Chief Medical Officer Option exercise 679 $5K
27 Jul 2026 Doyle Mittie Chief Medical Officer Option exercise 1,000 $13K
30 Jun 2026 Doyle Mittie Chief Medical Officer Option exercise 4,654 $51K

AVTX reported financials

SEC EDGAR XBRL

AVTX reported revenue of $59K for the fiscal year ended 31 Dec 2025. Net income over the same period was −$78.3M.

Figure Reported Period
Revenue $59K 31 Dec 2025 fiscal year
Net income −$78.3M 31 Dec 2025 fiscal year
Diluted EPS −$5.84 31 Dec 2025 fiscal year
Total assets $490.8M 30 Jun 2026 at period end
Total equity $448.7M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

AVTX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.83 —
31 Mar 2026 Q1 2026 $-0.98 —
31 Dec 2025 FY 2025 $-5.84 —
30 Sep 2025 Q3 2025 $-2.19 —
30 Jun 2025 Q2 2025 $-1.92 —
31 Mar 2025 Q1 2025 $-1.25 —
31 Dec 2024 FY 2024 $-20.91 —
30 Sep 2024 Q3 2024 $-2.83 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

AVTX institutional holders

SEC Form 13F

7 of the 45 institutional funds we track reported a AVTX position for the quarter ended 30 Jun 2026 — a combined $84.7M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Point72 Asset Management Added +160.6% shares 2,387,026 $44.1M
Balyasny Asset Management Held (±25%) +17.8% shares 861,711 $15.9M
Baker Bros. Advisors New position 550,000 $10.2M
Renaissance Technologies Added +197.4% shares 357,200 $6.6M
Citadel Advisors Added +67.2% shares 323,833 $6.0M
Two Sigma Investments Held (±25%) +4.1% shares 67,094 $1.2M
Man Group Held (±25%) −20.8% shares 36,876 $681K
Marshall Wace Exited
Millennium Management Exited

Source: SEC EDGAR 13F filings

AVTX fails-to-deliver

SEC CNS data

On 31 Aug 2026, 100 shares of AVTX failed to deliver (about $2K).

Settlement date Shares failed Notional % of shares out
31 Aug 2026 100 $2K <0.001%
27 Aug 2026 237 $5K <0.001%
26 Aug 2026 98,952 $2.0M 0.185%
25 Aug 2026 122 $2K <0.001%
24 Aug 2026 1,016 $20K 0.002%

Source: SEC fails-to-deliver (CNS) data